About Us
Real-time Quotes & News
Market Analysis
Trading Platform
Terms
Promotion
FAQ
Contact
繁
简
EN
繁
简
EN
Promotion
FAQ
Contact
Open Account
Contact Us

A Reuters poll showed that 33 out of 34 economists expect the Reserve Bank of Australia to raise interest rates by 25 basis points on September 29, bringing the cash rate to 4.60%.

2026-09-25

A Reuters poll showed that 33 out of 34 economists expect the Reserve Bank of Australia to raise interest rates by 25 basis points on September 29, bringing the cash rate to 4.60%.

Other News
2026-09-24

The Thailand Board of Investment aims to attract $80 billion in semiconductor investment by 2050.

The Thailand Board of Investment aims to attract $80 billion in semiconductor investment by 2050.
2026-09-24

Individual Stock News 1. China Xuyang Group (01907.HK) plans to invest RMB 507 million in Xiangfu New Energy to help it rapidly expand its production capacity. 2. Nine Dragons Paper (02689.HK) released its annual results: profit attributable to sha

Individual Stock News 1. China Xuyang Group (01907.HK) plans to invest RMB 507 million in Xiangfu New Energy to help it rapidly expand its production capacity. 2. Nine Dragons Paper (02689.HK) released its annual results: profit attributable to shareholders was RMB 3.581 billion, an increase of 102.62% year-on-year. 3. Vision Holdings (00862.HK) released its annual results: loss attributable to shareholders was HKD 437 million, an increase of 678.29% year-on-year. 4. Estun (02715.HK) plans to acquire approximately 44.8601% of Estun Jiangsu Intelligent's shares, increasing its stake to approximately 95.0107%. 5. Fosun Pharma (02696.HK) entered into a cooperation and licensing agreement with Amberstone for two T-cell connector products. 6. Asia Pacific Resources (01104.HK) released its annual results: profit attributable to shareholders was HK$1.711 billion, an increase of 601.69% year-on-year. 7. Hengrui Medicine (01276.HK): HRS-7172 tablets, adebelimab injection, and other drugs received drug clinical trial approval notices. 8. Lepu Biopharma (02157.HK): The clinical study results of CMG901 (AZD0901) were selected for the LBA and will be announced at the Chairman's Symposium. A total of 4 clinical study results were selected for the 2026 ESMO Congress.
Open Account
Demo Account
Contact Us
About Us Real-time Quotes & News Market Analysis
 Trading Platform Market Analysis Promotion Terms Promotion FAQ Contact
Copyright © 2026 Aspire Global Company Limited. All Rights Reserved.
Terms of Use and Privacy
Disclaimer

Disclaimer: ASPIRE is not responsible for the content of any analysis, advice, comment, suggestion, research report or market data in this website and links to third-party websites or resources. All the information mentioned above only represents the view of corresponding author. ASPIRE cannot and does not warrant the accuracy, validity, timeliness or completeness of any such information. You should conduct individual assessments and other proper research to make their investment decisions. The materials and information contained in this website are provided for reference only and do not constitute or form an offer, invitation, solicitation or investment advice or recommendation to acquire or dispose of any investment products or services. The price of any financial instruments described in this website may fall as well as rise. Past performance should not be taken as an indication of future performance. The risk disclosure statements do not purport to disclose or discuss all of the risks and other significant aspects of any financial instruments mentioned in this website. You should make your own appraisal of the risk and should consult to the extent necessary your own legal, tax, financial or other professional advisers in respect of any financial instruments mentioned in this website prior to entering into any transaction.

Risk Warning: Leveraged Precious Metals trading on margin carries significant risks and is not suitable for all investors. Please be sure to make investments within your own tolerance after fully understand the risks involved.

Registered & Business Address: Room 1905-1906, 19/F, Eastern Commercial Centre, 395-399 Hennessy Road, Hong Kong

Aspire Global Company Limited is not available to provide services for the residents of certain jurisdictions such as Afghanistan, the United States of America, the Islamic Republic of Iran, North Korean.